Triple Threat-NAD+,5-Amino 1 MQ and MOTS-C Current Research

The “Triple Threat” is a combined injectable formulation uniting three mechanistically distinct compounds—NAD+ (nicotinamide adenine dinucleotide), 5-Amino-1MQ (5-amino-1-methylquinolinium), and MOTS-c (mitochondrial ORF of the 12S rRNA type-c)—into a single subcutaneous injection targeting metabolic optimization, cellular energy restoration, and longevity.

The rationale for combining these three agents rests on convergent but non-redundant pathways: NAD+ directly replenishes the central redox cofactor that declines with age; 5-Amino-1MQ inhibits NNMT, the enzyme that degrades NAD+ precursors, thereby preserving and amplifying NAD+ pools; and MOTS-c activates AMPK, independently driving glucose utilization, fat oxidation, and mitochondrial biogenesis. Together, they create a multi-layered approach to restoring cellular energy metabolism.

Important caveat: The evidence base for each individual component comes primarily from preclinical (cell culture and animal) studies, with limited human clinical data. None of these compounds are FDA-approved therapeutics. The combined “Triple Threat” formulation has no published clinical trial data. This review synthesizes the available mechanistic and preclinical research to inform clinical decision-making.